Xilio Therapeutics Stock Quote XLO - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

1.07

Bid

1.05

Ask

1.15

Volume

144,163

1.02 Day's Range 1.11

0.49 52 Week Range 3.40

Market Cap

30.572M

Previous Close

1.01

Open

1.02

Last Trade

113

1.07

(formt)

Last Trade Time

Financial Volume

$ 155,169

VWAP

1.0763

Average Volume (3m)

1,291,523

Shares Outstanding

27,542,000

Dividend Yield

PE Ratio

-0.40

Earnings Per Share (EPS)

-2.77

Revenue

Net Profit

-76.4M

Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immuno... Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. The goal is to overcome the limitations of current I-O therapies by developing products with an improved therapeutic index. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

xiliotx.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Xilio Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker XLO. The last closing price for Xilio Therapeutics was $1.01. Over the last year, Xilio Therapeutics shares have traded in a share price range of $ 0.49 to $ 3.40.

Xilio Therapeutics currently has 27,542,000 shares outstanding. The market capitalization of Xilio Therapeutics is $30.57 million. Xilio Therapeutics has a price to earnings ratio (PE ratio) of -0.40.

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies

Dosing XTX301 at 45 ug/kg once every three weeks (dose level 3) in ongoing Phase 1 trial, nearly 100x the maximum tolerated dose of rhIL-12, with no dose-limiting toxicities observed to date...

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.18	-14.4	1.25	1.28	0.951	315210	1.07551685	CS
4	-0.25	-18.9393939394	1.32	1.63	0.951	1797909	1.44982189	CS
12	0.41	62.1212121212	0.66	1.93	0.5001	1291523	1.21456805	CS
26	-0.83	-43.6842105263	1.9	2.8938	0.49	683639	1.15336113	CS
52	-2.15	-66.7701863354	3.22	3.4	0.49	348575	1.18157302	CS
156	-13.93	-92.8666666667	15	27.95	0.49	187378	2.73493629	CS
260	-13.93	-92.8666666667	15	27.95	0.49	187378	2.73493629	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BDRXBiodexa Pharmaceuticals PLC	$ 1.3254 (82.86%)	70.82M
IBRXImmunityBio Inc	$ 7.35 (43.84%)	40.28M
AGENAgenus Inc	$ 11.685 (40.78%)	3.37M
ULHUniversal Logistics Holdings Inc	$ 45.63 (38.74%)	484.22k
NIVFNewGenIvf Group Ltd	$ 1.77 (36.15%)	57.78M
MFImF International Ltd	$ 2.3153 (-77.82%)	21.23M
NWGLNature Wood Group Ltd	$ 5.05 (-70.03%)	2.48M
ICLKiClick Interactive Asia Group Ltd	$ 1.21 (-52.17%)	719.95k
NUWENewellis Inc	$ 0.1695 (-41.35%)	18.46M
SGBXSafe and Green Holdings Corporation	$ 0.1469 (-32.92%)	8.39M
PEGYPineapple Energy Inc	$ 0.065499 (26.20%)	325.57M
SQQQProShares UltraPro Short QQQ	$ 11.43 (-4.75%)	137.28M
INTCIntel Corporation	$ 31.88 (-9.20%)	119.84M
TSLATesla Inc	$ 168.29 (-1.11%)	109.84M
SOFISoFi Technologies Inc	$ 7.87 (3.69%)	88.63M